Giving Compass' Take:
- Mary Casert and Jennifer Nayak, infectious disease experts at the University of Rochester Medical Center, share updates on the new pediatric RSV vaccines.
- What are the access issues during new vaccine rollouts? How can donors support healthcare systems in increasing accessibility?
- Learn about the surging RSV infections that started in 2022.
What is Giving Compass?
We connect donors to learning resources and ways to support community-led solutions. Learn more about us.
Infants have new protections against respiratory syncytial virus, but for now, availability is limited. Here, experts bring you up to speed on what you need to know about the new pediatric RSV immunizations.
Respiratory syncytial virus (RSV) is a major cause of illness in young children and is the leading reason why infants are hospitalized. Until recently, this viral infection was difficult to prevent or treat.
Now, two new effective prevention methods are available. The first is nirsevimab, which is approved and recommended for infants 0-8 months old and select older infants with certain high risk conditions. The second is a new immunization available for pregnant patients, called Abrysvo, which leads to a 57% decrease in the chance of infant hospitalization due to RSV.
Availability of nirsevimab is limited, and newborn children staying in NICUs currently have priority for receiving the immunization. Abrysvo is more widely available at obstetrician offices and local Walgreens pharmacies.
But, how do the immunizations work? And are they safe and effective?
Nirsevimab has been in development for several years and was created specifically for newborns aged 0-8 months and select older infants at risk for severe disease from RSV. Unlike traditional vaccines that stimulate immune memory and “train” your body to recognize RSV, nirsevimab provides antibodies directly to fight the virus.
While a traditional vaccine provides a cook book-like recipe that the body uses to build immunity over several weeks to fight RSV, nirsevimab is ready to fight RSV as soon as its given.
Fortunately, because it is active immediately, nirsevimab given to newborns provides protection against RSV at the ages that children are most at risk for severe disease (0-8 months). In fact, nirsevimab has been shown to decrease the risk of RSV-related hospitalization and avoid the disruption to a family’s routine that a hospitalization causes.
In addition to babies 0-8 months during their first RSV season, children from 8-24 months old who are at high risk for RSV infection may be eligible to receive nirsevimab during their second RSV season. For more information, contact a health care provider.
Read the full article about RSV vaccines by Scott Hesel at Futurity.